Norgine Receives Approval from Swissmedic for PEDMARQSI® to Combat Hearing Loss in Children Norgine's PEDMARQSI® has gained regulatory approval in Switzerland, marking a significant step in preventing cisplatin-induced hearing loss in pediatric patients. This innovative treatment addresses a critical medical need.

Norgine Receives Approval from Swissmedic for PEDMARQSI® to Combat Hearing Loss in Children #None #Norgine #CISPLATIN #PEDMARQSI

Norgine's PEDMARQSI Gets Swissmedic Green Light: A Breakthrough in Preventing Hearing Loss in Children Norgine has received Swissmedic approval for PEDMARQSI, a groundbreaking treatment to prevent cisplatin-induced hearing loss in young cancer patients.

Norgine's PEDMARQSI Gets Swissmedic Green Light: A Breakthrough in Preventing Hearing Loss in Children #Amsterdam #Switzerland #Norgine #PEDMARQSI #Swissmedic

Norgine's PEDMARQSI® Approved to Prevent Cisplatin-Induced Hearing Loss in Children Norgine has announced that Swissmedic has approved PEDMARQSI®, the first treatment for preventing cisplatin-induced hearing loss in children, fulfilling an unmet medical need.

Norgine's PEDMARQSI® Approved to Prevent Cisplatin-Induced Hearing Loss in Children #Amsterdam #Switzerland #Norgine #CISPLATIN #PEDMARQSI

Norgine's PEDMARQSI® Receives Swissmedic Approval to Prevent Hearing Loss in Kids Norgine has announced that its drug PEDMARQSI® has received approval from Swissmedic to prevent cisplatin-induced hearing loss in children under 18.

Norgine's PEDMARQSI® Receives Swissmedic Approval to Prevent Hearing Loss in Kids #Amsterdam #Switzerland #Norgine #CISPLATIN #PEDMARQSI®

Norgine's £23 Million Investment Sparks Expansion of Welsh Manufacturing Capabilities Norgine invests £23 million in its Welsh facility, totaling over £50 million since 2022, enhancing medicine manufacturing and job creation.

Norgine's £23 Million Investment Sparks Expansion of Welsh Manufacturing Capabilities #United_Kingdom #Norgine #Medicines #Hengoed

Norgine Announces Major Investment to Boost Pharmaceutical Manufacturing in Wales Norgine is making a significant £23 million investment in Hengoed, Wales, to enhance its manufacturing capacity and create new jobs, securing the supply of medicines.

Norgine Announces Major Investment to Boost Pharmaceutical Manufacturing in Wales #United_Kingdom #pharmaceuticals #Norgine #Hengoed

Norgine Boosts Drug Manufacturing in Wales with £23 Million Investment In a strategic move to expand operations, Norgine announces a £23 million investment in its Wales facility, totaling over £50 million since 2022, aimed at enhancing medication manufacturing capabilities.

Norgine Boosts Drug Manufacturing in Wales with £23 Million Investment #United_Kingdom #Norgine #Drug_Manufacturing #Wales #Hengoed

Norgine Invests £23 Million to Expand Pharmaceutical Manufacturing in Wales Norgine has announced a new investment of £23 million to enhance its pharmaceuticals manufacturing facility in Hengoed, Wales, creating jobs and boosting local production.

Norgine Invests £23 Million to Expand Pharmaceutical Manufacturing in Wales #United_Kingdom #pharmaceuticals #Norgine #Hengoed

Norgine Announces Major Investment of £23 Million to Enhance Drug Manufacturing in Wales Norgine, a leading European pharmaceutical company, invests £23 million to expand drug manufacturing in Wales, supporting local jobs and innovation.

Norgine Announces Major Investment of £23 Million to Enhance Drug Manufacturing in Wales #United_Kingdom #pharmaceutical #Norgine #Wales #Hengoed

Norgine Celebrates EU CHMP Opinion on Mavorixafor for WHIM Syndrome Treatment Norgine B.V. recognizes a major regulatory milestone with CHMP's recommendation for mavorixafor, a treatment for WHIM syndrome in the EU. Final decision is anticipated soon.

Norgine Celebrates EU CHMP Opinion on Mavorixafor for WHIM Syndrome Treatment #Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM_syndrome

Norgine Celebrates CHMP's Support for Mavorixafor in Treating WHIM Syndrome Norgine welcomes a positive opinion by the CHMP regarding mavorixafor's approval for WHIM syndrome in Europe, marking a significant milestone.

Norgine Celebrates CHMP's Support for Mavorixafor in Treating WHIM Syndrome #None #Norgine #Mavorixafor #WHIM_syndrome

Norgine Celebrates Positive CHMP Opinion for Mavorixafor Approval in the EU for WHIM Syndrome Norgine has welcomed the CHMP's positive recommendation for Mavorixafor to treat WHIM syndrome in the EU, paving the way for the first approved treatment.

Norgine Celebrates Positive CHMP Opinion for Mavorixafor Approval in the EU for WHIM Syndrome #Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM_syndrome

Norgine Enthusiastically Welcomes CHMP's Positive Opinion for Mavorixafor Approval Norgine celebrates the positive CHMP opinion recommending approval for mavorixafor, marking an essential step for WHIM syndrome treatment in Europe.

Norgine Enthusiastically Welcomes CHMP's Positive Opinion for Mavorixafor Approval #None #Norgine #Mavorixafor #WHIM_syndrome

Norgine Celebrates Positive Recommendation for Mavorixafor Approval in Europe for WHIM Syndrome Norgine B.V. announces a positive recommendation from CHMP for mavorixafor's approval in Europe, a significant step for WHIM syndrome treatment.

Norgine Celebrates Positive Recommendation for Mavorixafor Approval in Europe for WHIM Syndrome #Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM_syndrome

Norgine Expands Hepatology and Specialty Portfolio with Exclusive Licensing Deal Norgine has secured an exclusive licensing agreement with Vir Biotechnology to expand its hepatology product offerings, addressing unmet medical needs.

Norgine Expands Hepatology and Specialty Portfolio with Exclusive Licensing Deal #United_Kingdom #Norgine #Uxbridge #Vir_Biotechnology #Chronic_Hepatitis_D

Norgine Expands Its Hepatology Portfolio with Exclusive Licensing Agreement Norgine enhances its portfolio of hepatology products through a significant licensing agreement with Vir Biotechnology, focusing on hepatitis delta treatment.

Norgine Expands Its Hepatology Portfolio with Exclusive Licensing Agreement #None #Norgine #Vir_Biotechnology #Hepatitis_Delta

Norgine Expands Hepatology Portfolio with Exclusive Licensing Agreement for Innovative Therapy Norgine has announced an exclusive agreement to market a new therapy for chronic hepatitis delta, reinforcing its commitment to innovative patient care.

Norgine Expands Hepatology Portfolio with Exclusive Licensing Agreement for Innovative Therapy #United_Kingdom #Norgine #Uxbridge #Vir_Biotechnology #Hepatitis_Delta

Norgine and Vir Biotechnology Join Forces to Combat Chronic Hepatitis Delta through Innovative Licensing Deal Norgine has forged an exclusive partnership with Vir Biotechnology to market an innovative treatment for chronic hepatitis delta across Europe and beyond.

Norgine and Vir Biotechnology Join Forces to Combat Chronic Hepatitis Delta through Innovative Licensing Deal #UK #Norgine #Uxbridge #Hepatology #Vir_Biotechnology

Norgine Expands Specialty Pharmaceutical Portfolio with Licensing Deal with Vir Biotechnology Norgine has secured an exclusive licensing agreement with Vir Biotechnology to commercialize a groundbreaking treatment for chronic hepatitis delta, targeting high unmet medical needs across Europe and Oceania.

Norgine Expands Specialty Pharmaceutical Portfolio with Licensing Deal with Vir Biotechnology #UK #Norgine #Uxbridge #Vir_Biotechnology #Hepatitis_Delta

#WODC2025 inspiring key note about Europe‘s life science strategy ✨
#innovation #research #takeda #norgine #europeancommission #eurordis

Norgine Completes Acquisition of Theravia to Expand Rare Disease Therapies Norgine has successfully acquired Theravia, enhancing its capabilities in rare disease therapies and expanding its reach to underserved patient populations.

Norgine Completes Acquisition of Theravia to Expand Rare Disease Therapies #Paris #France #Rare_Diseases #Norgine #Theravia

Norgine Successfully Completes Acquisition of Theravia to Expand Rare Disease Portfolio Norgine has announced the successful acquisition of Theravia, enhancing its portfolio in rare diseases and improving treatment options for patients.

Norgine Successfully Completes Acquisition of Theravia to Expand Rare Disease Portfolio #None #pharmaceuticals #Norgine #Theravia

Norgine Embarks on a New Venture with The Acquisition of Theravia Norgine has completed the acquisition of Theravia, a move aimed at enhancing their portfolio in rare disease therapies and addressing high unmet medical needs.

Norgine Embarks on a New Venture with The Acquisition of Theravia #None #pharmaceuticals #Norgine #Theravia

Norgine Completes Acquisition of Theravia, Expanding Rare Disease Portfolio Norgine has finalized the acquisition of Theravia, significantly enhancing its portfolio targeting rare disease treatments and expanding patient access across markets.

Norgine Completes Acquisition of Theravia, Expanding Rare Disease Portfolio #Paris #France #pharmaceutical #Norgine #Theravia

Norgine Successfully Completes Acquisition of Theravia to Expand Rare Disease Portfolio Norgine has finalized its acquisition of Theravia, aiming to strengthen its portfolio of therapies for rare diseases and enhance patient access to vital medications.

Norgine Successfully Completes Acquisition of Theravia to Expand Rare Disease Portfolio #None #pharmaceuticals #Norgine #Theravia

Swissmedic Grants Approval for IFINWIL® to Combat High-Risk Neuroblastoma in Children Norgine celebrates Swissmedic's approval of IFINWIL® for treating high-risk neuroblastoma in children, enhancing treatment access in Europe.

Swissmedic Grants Approval for IFINWIL® to Combat High-Risk Neuroblastoma in Children #Switzerland #Neuroblastoma #Norgine #IFINWIL® #Uxbirdge

Swissmedic Grants Approval for IFINWIL® to Treat Children with High-Risk Neuroblastoma Norgine celebrates Swissmedic's approval of IFINWIL® for pediatric high-risk neuroblastoma, a solution that aims to enhance treatment outcomes for affected children.

Swissmedic Grants Approval for IFINWIL® to Treat Children with High-Risk Neuroblastoma #Switzerland #Neuroblastoma #Norgine #IFINWIL® #Ubxbridge

Swissmedic Grants Approval for IFINWIL® to Treat High-Risk Neuroblastoma in Children Norgine announces Swissmedic's approval of IFINWIL® for high-risk neuroblastoma in children, enhancing treatment options for pediatric patients.

Swissmedic Grants Approval for IFINWIL® to Treat High-Risk Neuroblastoma in Children #Switzerland #Neuroblastoma #Norgine #IFINWIL #Ubxbridge

Swissmedic Approves IFINWIL® for Children with High-Risk Neuroblastoma Norgine announces that Swissmedic has approved IFINWIL® for pediatric patients with high-risk neuroblastoma, marking a vital advancement in treatment options for children.

Swissmedic Approves IFINWIL® for Children with High-Risk Neuroblastoma #Switzerland #Eflornithine #Norgine #IFINWIL® #Ubxbridge

Swissmedic Approves IFINWIL® for High-Risk Neuroblastoma in Children Norgine announces Swissmedic's approval of IFINWIL® for treating high-risk neuroblastoma in young children, providing a new hope in pediatric oncology.

Swissmedic Approves IFINWIL® for High-Risk Neuroblastoma in Children #Switzerland #Neuroblastoma #Norgine #IFINWIL® #Ubxbridge